Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.

After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left scrambling to figure out what to do.

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking the drug.The move comes less than a day after Pfizer abruptly announced a worldwide withdrawal of the drug,